KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Current Assets (2017 - 2025)

Novartis Ag (NVS) has disclosed Current Assets for 9 consecutive years, with $30.5 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 2.55% to $30.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.5 billion through Dec 2025, up 2.55% year-over-year, with the annual reading at $30.5 billion for FY2025, 2.55% up from the prior year.
  • Current Assets hit $30.5 billion in Q4 2025 for Novartis Ag, up from $29.7 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $45.7 billion in Q4 2021 to a low of $29.7 billion in Q4 2024.
  • Historically, Current Assets has averaged $34.7 billion across 5 years, with a median of $30.5 billion in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 54.07% in 2021 and later dropped 19.27% in 2022.
  • Year by year, Current Assets stood at $45.7 billion in 2021, then dropped by 19.27% to $36.9 billion in 2022, then dropped by 17.42% to $30.5 billion in 2023, then decreased by 2.55% to $29.7 billion in 2024, then rose by 2.55% to $30.5 billion in 2025.
  • Business Quant data shows Current Assets for NVS at $30.5 billion in Q4 2025, $29.7 billion in Q4 2024, and $30.5 billion in Q4 2023.